Worth Watching Stocks: Array BioPharma Inc. (NASDAQ:ARRY)


Array BioPharma Inc. (NASDAQ:ARRY) added 4.44% and closed its last session at $8.23. The stock has the market capitalization of $1.39 Billion with the total outstanding shares of 168.55 Million. Array BioPharma Inc.. has Analysts’ Mean Recommendation of 1 between the scale of 1 to 5 (1 represents Strong Buy and 5 means Sell). The stock currently has P/E of 0 for trailing twelve months while its Forward P/E is 0.

Array BioPharma Inc. (NASDAQ:ARRY) touched its 52-Week High of $8.27 on Nov 21, 2016 while it’s 52-Week Low of $2.38 on Feb 11, 2016. The company currently has Return on Assets of -54.9 percent, Return on Equity of 406% and Return on Investment of -108.5 percent. The stock currently showing Weekly Volatility of 5.52%% and Monthly Volatility of 6.20% Percent with Average True Range of 0.4 and Beta of 2.2.

The 8 analysts offering 12-month price forecasts for Array Biopharma Inc have a median target of 9.50, with a high estimate of 15.00 and a low estimate of 8.00. The median estimate represents a +15.43% increase from the last price of 8.23.

Press Release:

The Company and Pierre Fabre on 9 November jointly declared new results from the pivotal Phase 3 COLUMBUS trial of binimetinib plus encorafenib (bini/enco) treatment in BRAF-mutant melanoma patients at the Society for Melanoma Research Annual Congress. The study met its primary endpoint, with the combination of bini/enco significantly improving progression free survival (PFS) compared with vemurafenib, a BRAF inhibitor, alone. The combination of bini/enco was generally well-tolerated and reported adverse events (AEs) were overall consistent with previous published clinical trial results for the bini/enco combination in BRAF-mutant melanoma patients.

The combination of bini/enco was generally well-tolerated and reported AEs were overall consistent with previous bini/enco combination clinical trial results in BRAF-mutant melanoma patients.

  • Grade 3/4 AEs which occurred in more than 5% of patients receiving bini/enco included increased gamma-glutamyltransferase (GGT), increased blood creatine phosphokinase (CK), and hypertension
  • The incidence of AEs of special interest (toxicities commonly associated with commercially available MEK+BRAF-inhibitor treatments), for patients receiving bini/enco included (% of patients): rash (23%), pyrexia (18%), retinal pigment epithelial detachment (13%) and photosensitivity (5%)

Company Profile:

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company’s proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.